824-75-9 | 4-Fluorobenzamide

Packsize	Purity	Availability	Price	Discounted Price
5g	98%	in stock	$5.00	$4.00
10g	98%	in stock	$8.00	$6.00
25g	98%	in stock	$11.00	$8.00

Description

• Catalog Number: AB67519
• Chemical Name: 4-Fluorobenzamide
• CAS Number: 824-75-9
• Molecular Formula: C7H6FNO
• Molecular Weight: 139.127
• MDL Number: MFCD00007992
• SMILES: NC(=O)c1ccc(cc1)F
• NSC Number: 102765

Computed Properties

• Complexity: 130
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 10
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 1
• XLogP3: 0.9

Literature

• Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20120501

• Molecular evolution of the neuropeptide S receptor.

  PloS one 20120101

• Metabolic stability of new anticonvulsants in body fluids and organ homogenates.

  Acta poloniae pharmaceutica 20120101

• Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68).

  Journal of medicinal chemistry 20110428

• The asthma candidate gene NPSR1 mediates isoform specific downstream signalling.

  BMC pulmonary medicine 20110101

• Multiple polymorphisms affect expression and function of the neuropeptide S receptor (NPSR1).

  PloS one 20110101

• Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor.

  Medicinal research reviews 20100901

• 4-Substituted-7-N-alkyl-N-acetyl 2-aminobenzothiazole amides: drug-like and non-xanthine based A2B adenosine receptor antagonists.

  Bioorganic & medicinal chemistry letters 20100715

• Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68.

  Peptides 20100501

• Importance of extracellular loop one of the neuropeptide S receptor for biogenesis and function.

  Peptides 20100101

• Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy.

  Infection and drug resistance 20100101

• Design, synthesis, and preliminary in vitro and in vivo evaluation of N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide ([18F]-DAFBA): a novel potential PET probe to image melanoma tumors.

  Bioconjugate chemistry 20090318

• Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor.

  The Journal of pharmacology and experimental therapeutics 20080601

• Raltegravir: first in class HIV integrase inhibitor.

  Therapeutics and clinical risk management 20080401

• [New derivatives of eremomycin containing (15)n or f atoms for NMR study].

  Bioorganicheskaia khimiia 20080101

• Raltegravir in the management of HIV-infected patients.

  Drug design, development and therapy 20080101

• From dihydroxypyrimidine carboxylic acids to carboxamide HIV-1 integrase inhibitors: SAR around the amide moiety.

  Bioorganic & medicinal chemistry letters 20070115

• 19F NMR chemical shifts induced by a helical peptide.

  Chembiochem : a European journal of chemical biology 20060701

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.

  Bioorganic & medicinal chemistry letters 20051015